
Fertility Expert Dr. Banafsheh Kashani Shares Advice for Couples Trying to Conceive this Holiday Season
Dr. Kashani offers insights for couples trying to conceive during the holidays, from nutrition and stress management to products to consider.
Florida / New York
Medical Device News Magazine publishes feature articles from industry experts on medical device technology, regulation, reimbursement, and business strategy.
Dr. Kashani offers insights for couples trying to conceive during the holidays, from nutrition and stress management to products to consider.
The creation of CAR T cell therapy begins with collection of the patient’s blood and separation of the lymphocytes. These include T cells, B cells, and innate lymphoid cells, all of which are separated through apheresis (leukapheresis). It is this separation process which, if optimized, has the potential to revolutionize immunotherapy treatments for cancer patients.
The latest results from a clinical trial presented today at the VEITHsymposium in New York City demonstrate how new living blood vessels created through restorative medical devices have become reality and can open unthinkable treatment avenues for patients. Xeltis is developing cardiovascular devices, namely artificial vessels and valves, that gradually create living and long-lasting vessels made of patients’ own, new healthy tissue.
In the dynamic realm of entrepreneurship, where seasoned professionals often take center stage, the story of Sai Mattapalli and Rohan Kalahasty — both 17-year-old high school seniors — emerges as a beacon of inspiration.
Within two years, the U.S. will have a shortage of 98,700 medical and lab technologists and more than 80% of health systems are currently reporting shortages in their radiology departments. More than half of the radiologists in the U.S. are 55 and older, and the flow of residents to fill the gap isn’t nearly big enough. The staffing shortage is even more acute among radiation technologists and in the U.K., 97% of radiology departments cannot meet diagnostic reporting requirements.
Dr. Litwin advises, “Approximately 60 study sites worldwide are participating in RESPONDER-HF, a randomized clinical trial of the Corvia Atrial Shunt.” What to know more about this life-saving device? Read what this expert has to say.
Copyright © 2025 Medical Device News Magazine, a division of PTM Healthcare Marketing, Inc. All Rights Reserved
Hours:
M – F 8 am – 5 pm
Florida / New York
Phone: 561.316.3330